Germline splicing mutations of CDKN2A predispose to melanoma

[1]  A. Howell,et al.  Germline mutation of ARF in a melanoma kindred. , 2002, Human molecular genetics.

[2]  S. Kern,et al.  Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma–pancreatic carcinoma–prone families , 2002, Cancer.

[3]  J. A. Bishop,et al.  A deep intronic mutation in CDKN2A is associated with disease in a subset of melanoma pedigrees. , 2001, Human molecular genetics.

[4]  J. Malvehy,et al.  A melanoma-associated germline mutation in exon 1β inactivates p14ARF , 2001, Oncogene.

[5]  M. Genuardi,et al.  CDKN2A germline splicing mutation affecting both p16ink4 and p14arf RNA processing in a melanoma/neurofibroma kindred , 2001, Genes, chromosomes & cancer.

[6]  J. Struewing,et al.  A common founder for the V126D CDKN2A mutation in seven North American melanoma-prone families , 2001, British Journal of Cancer.

[7]  Å. Borg,et al.  Haplotype analysis and age estimation of the 113insR CDKN2A founder mutation in Swedish melanoma families , 2001, Genes, chromosomes & cancer.

[8]  J. Struewing,et al.  A single genetic origin for the G101W CDKN2A mutation in 20 melanoma-prone families. , 2000, American journal of human genetics.

[9]  M. Tucker,et al.  Lack of germline CDK6 mutations in familial melanoma , 2000, Oncogene.

[10]  M. Tsai,et al.  Tumor suppressor INK4: determination of the solution structure of p18INK4C and demonstration of the functional significance of loops in p18INK4C and p16INK4A. , 1999, Biochemistry.

[11]  David Hogg,et al.  Mutation of the CDKN2A 5' UTR creates an aberrant initiation codon and predisposes to melanoma , 1999, Nature Genetics.

[12]  R. MacKie,et al.  CDKN2A germline mutations in U.K. patients with familial melanoma and multiple primary melanomas. , 1998, The Journal of investigative dermatology.

[13]  M. Tucker,et al.  CDKN2A mutations in multiple primary melanomas. , 1998, The New England journal of medicine.

[14]  H. J. Kim,et al.  Tumor suppressor p16INK4A: determination of solution structure and analyses of its interaction with cyclin-dependent kinase 4. , 1998, Molecular cell.

[15]  D. Hogg,et al.  Role of the Cyclin-Dependent Kinase Inhibitor CDKN2A in Familial Melanoma , 1998, Journal of cutaneous medicine and surgery.

[16]  C. Moskaluk,et al.  Novel germline p16INK4 allele (Asp145Cys) in a family with multiple pancreatic carcinomas , 1998 .

[17]  P. Pollock,et al.  Haplotype analysis of two recurrent CDKN2A mutations in 10 melanoma families: Evidence for common founders and independent mutations , 1998, Human mutation.

[18]  Ernest D. Laue,et al.  Structure of the cyclin-dependent kinase inhibitor p19Ink4d , 1997, Nature.

[19]  M. Tucker,et al.  Affected members of melanoma‐prone families with linkage to 9p21 but lacking mutations in CDKN2A do not harbor mutations in the coding regions of either CDKN2B or p19ARF , 1997 .

[20]  D. Quelle,et al.  Cancer-associated mutations at the INK4a locus cancel cell cycle arrest by p16INK4a but not by the alternative reading frame protein p19ARF. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[21]  L. Sandkuijl,et al.  CDKN2 explains part of the clinical phenotype in Dutch familial atypical multiple‐mole melanoma (FAMMM) syndrome families , 1995, Melanoma research.

[22]  W. Clark,et al.  Germline p16 mutations in familial melanoma , 1994, Nature Genetics.

[23]  E. Coligan.  Current protocols in immunology , 1991 .

[24]  Marvin B. Shapiro,et al.  RNA splice junctions of different classes of eukaryotes: sequence statistics and functional implications in gene expression. , 1987, Nucleic acids research.